Omvoh has additional ongoing trials in Crohn's disease and UC, including studies to evaluate the long-term efficacy and safety of Omvoh in pediatric patients and adults, and a Phase 4 real-world ...

New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

Common adverse reactions included upper respiratory tract infections, injection site reactions, headache, arthralgia and elevated liver tests. In addition, the Omvoh labeling includes warnings and ...

Check the label to be sure. Try to choose 100% brewer's yeast without ... Yeast-derived β-1,3/1,6 glucan, upper respiratory tract infection and innate immunity in older adults. Nutrition. 2017 Jul-Aug ...

The most common side effects of Ocrevus for those with PPMS are upper respiratory tract infections ... Gilenya—fingolimod hcl capsule [drug label]. Food and Drug Administration. Tascenso ODT label.

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...